1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,336 | 0,339 | 15:34 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Sensorion announces $71.9m reserved offering to expand gene therapy pipeline | 14 | Pharmaceutical Technology | ||
| Mi | Sensorion secures €60 million investment led by Sanofi for hearing loss therapies | 14 | Investing.com | ||
| Mi | Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline | 1.095 | Business Wire | Sanofi's investment marks the entry of a strategic shareholder Support from existing investors Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners Participation... ► Artikel lesen | |
| 19.12.25 | Sensorion to Present at the 44th Annual J.P. Morgan Healthcare Conference | 320 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within... ► Artikel lesen | |
| 08.12.25 | Sensorion gene therapy shows early promise in pediatric hearing loss | 3 | Investing.com | ||
| 08.12.25 | Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501's Audiogene Phase 1/2 Trial | 375 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 17.09.25 | Sensorion reports 1H results | 2 | Seeking Alpha | ||
| 17.09.25 | Sensorion Reports Wider Loss In H1 | 1 | RTTNews | ||
| SENSORION Aktie jetzt für 0€ handeln | |||||
| 17.09.25 | Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report | 421 | Business Wire | Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company's gene therapy candidate being developed to treat a specific... ► Artikel lesen | |
| 04.09.25 | Sensorion Announces its Participation in the 60th Annual Inner Ear Biology Workshop | 414 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 15.08.25 | Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux | 441 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 31.07.25 | Sensorion Announces Its Participation In Upcoming Investor Conferences | 524 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 29.07.25 | Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial | 402 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN),a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 01.07.25 | Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial | 461 | Business Wire | SENS-501, including the surgical delivery of the gene therapy, shows a good safety profile in all patients treated so far Three-month results from a SENS-501 treated toddler in the first... ► Artikel lesen | |
| 13.05.25 | Sensorion Publishes Results of Combined Shareholders' General Meeting Resolutions | 482 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 06.05.25 | Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting | 444 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 25.04.25 | Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting | 680 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 18.04.25 | Sensorion Provides Preliminary Documents for the Combined Shareholders' General Meeting of May 12, 2025 | 592 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 16.04.25 | Sensorion to Host a Symposium during ISIET's International Conference on Inner Ear Therapies on April 26, 2025 | 487 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen | |
| 02.04.25 | Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director | 504 | Business Wire | Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 91,80 | -0,65 % | BioNTech-Aktie: Hält das starke Momentum? | Die BioNTech-Aktie meldet sich 2026 eindrucksvoll zurück. Seit Jahresbeginn liegt der Titel um rund 23% im Plus, notiert bei knapp 120 US$ und zählt damit zu den auffälligen Gewinnern an der Börse.... ► Artikel lesen | |
| EVOTEC | 6,410 | +8,64 % | Puma-Übernahme wird konkreter! Als nächstes Evotec und Silver Viper Aktien kaufen? | Schon länger gibt es Übernahmespekulationen rund um Puma. Jetzt hat sich Anta 29 % am deutschen Sportartikelkonzern gesichert. Dafür zahlen die Chinesen 35 EUR je Aktie. An der Börse hält sich die Euphorie... ► Artikel lesen | |
| MEDIGENE | 0,042 | -11,34 % | Medigene: Zurückziehung - 18.11.2025 | ||
| MODERNA | 36,885 | +2,17 % | Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer... ► Artikel lesen | |
| VALNEVA | 3,906 | 0,00 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| AMGEN | 293,00 | +0,21 % | Sanofi und Amgen: Droht diesem Ansatz das Aus? AKTIONÄR-Tipp profitiert! | Viele große Pharma- und Biotech-Firmen sind auf der Suche nach neuen Behandlungsansätzen für die Atopische Dermatitis (Neurodermitis). So auch die großen Branchenvertreter Amgen und Sanofi, die mit... ► Artikel lesen | |
| EPIGENOMICS | 0,872 | +0,23 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Jahresergebnis zum... ► Artikel lesen | |
| NOVAVAX | 7,338 | -0,37 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| BIOGEN | 150,90 | -0,63 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| BIOFRONTERA | 2,200 | -7,17 % | BIOFRONTERA AG - Stabilität als strategisches Signal | ||
| HEIDELBERG PHARMA | 2,810 | -1,06 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma erhält Meilensteinzahlung des Partners Takeda | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma erhält Meilensteinzahlung des Partners Takeda
29.01.2026 / 13:27 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,600 | +2,29 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| NANOREPRO | 1,500 | -2,60 % | NanoRepro ordnet Aufsichtsrat nach außerordentlicher HV neu | Die Aktionäre der NanoRepro AG haben auf der außerordentlichen Hauptversammlung vom 16. Januar 2026 den Aufsichtsrat neu zusammengesetzt. Neu gewählt wurden Gunter Heneis, Michael Herrmann und Konstantin... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 17,000 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen |
Das Unternehmen SENSORION SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,318 Euro und damit +4,95 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENSORION SA finden Sie auf Wallstreet Online.